Context Therapeutics (NASDAQ: CNTX) has announced positive interim Phase 1 clinical data for its CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in advanced, late-line platinum-resistant ovarian cancer (PROC).
According to Context, the data are as of a May 29, 2026 data cutoff from the ongoing CTIM-76 Phase 1 study.
In a statement, Martin Lehr, CEO of Context, commented, “We are encouraged by the continued development of CTIM-76 as a potentially best-in-class CLDN6 T cell engager that may offer a much-needed new therapeutic approach for patients with platinum-resistant ovarian cancer. In our first clinical presentation of dose-escalation data, weekly administration of CTIM-76 produced compelling anti-tumor activity and a well-tolerated safety profile in heavily pretreated patients, many of whom had extensive prior exposure to antibody-drug conjugates. Building on this encouraging data, we have advanced into the next phase of development, where we will evaluate CTIM-76 administered every three weeks. These results are expected to inform subsequent Phase 1b dose expansion in 2027.”
